Results 101 to 110 of about 1,060,485 (284)

Developing Highly Effective Nanoparticle mRNA Therapeutic for Pediatric Acute Respiratory Distress Syndrome

Advanced Science, EarlyView.
Sepsis‑induced pediatric acute respiratory distress syndrome suppresses FOXF1 in lung endothelial cells which causes life‐threatening lung damage. To counter this, researchers developed nanoparticles that specifically target these cells and deliver FOXF1 mRNA.
Zicheng Deng, Wen Gao, Jonathan Do, Danli Lu, Ying‐Wei Lan, Andreas Damianos, Gautam Verma, Ali Al Siraj, Isabella Lowry, Lance Peter, Nicholas E. Banovich, Fei Sun, Hua He, Tanya V. Kalin, Vladimir V. Kalinichenko   +14 more
wiley   +1 more source

Patient‐Derived Fibroblasts as a Clinically Relevant Model of Kearns–Sayre Syndrome

Annals of Neurology, EarlyView.
Objective Kearns–Sayre syndrome (KSS) is characterized by single large‐scale mitochondrial DNA deletions and by severe early‐onset clinical manifestations with neurological involvement. Reliable disease models, as well as validated biomarkers or effective treatments, are lacking.
Laura Valls‐Roca, Adrià Vilaseca‐Capel, Judith Cantó‐Santos, Ester Tobías, Félix Andújar‐Sánchez, Laia Farré‐Tarrats, Frederic Tort, Carles Rentero, Carlos Enrich, Virginia López, Juan R. Tejedor, Anna Esteve‐Codina, Cristina Núñez de Arenas, Pedro J. Moreno‐Lozano, José C. Milisenda, Mar O'Callaghan, Teresa García‐Silva, Montserrat Morales‐Conejo, Mario F. Fraga, Rafael Artuch, Miguel Á. Martín, José M. Cuezva, Ana Matas, Glòria Garrabou, Mariona Guitart‐Mampel   +24 more
wiley   +1 more source

Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial

Thrombosis Journal
Background Atypical hemolytic uremic syndrome (aHUS) is a rare disease with poor outcomes when untreated, in which ravulizumab or eculizumab are the standard of care where available.
Masanori Matsumoto, Akihiko Shimono, Jun Yokosawa, Keiichiro Hirose, Edward Wang, Shoichi Maruyama   +5 more
doaj   +1 more source

Effects of freezer storage time on levels of complement biomarkers

BMC Research Notes, 2017
Background There is uncertainty regarding how stable complement analytes are during long-term storage at – 80 °C. As part of our work program we have measured 17 complement biomarkers (C1q, C1 inhibitor, C3, C3a, iC3b, C4, C5, C9, FB, FD, FH, FI, TCC, Bb,
Angharad R. Morgan, Caroline O’Hagan, Samuel Touchard, Simon Lovestone, B. Paul Morgan   +4 more
doaj   +1 more source

Circulating Exosomes Drive Persistent Neuronal Dysfunction in Post‐Herpetic Neuralgia Patients

Annals of Neurology, EarlyView.
Proposed model of exosome‐mediated neuronal dysfunction in post‐herpetic neuralgia (PHN). (1) Circulating, non‐pathogenic exosomes maintain homeostatic processes in healthy skin, where sensory nerve fibers innervate the epidermis and dermis. (2) During acute zoster, reactivating varicella zoster virus (VZV) travels down neurites to the skin causing ...
Christy S. Niemeyer, Seth Frietze, Serena W.R. Lewis, Emily C. Artman, Christina Coughlan, Safa I. Vaseemuddin, Arianna Gentile Polese, Maria A. Nagel, Stephen K. Tyring, Fyona Okundia, Anthony J. Saviola, Gary C. Curhan, Sharon G. Curhan, Diego Restrepo, Andrew N. Bubak   +14 more
wiley   +1 more source

Inhibition of monocyte complement receptor enhancement by low molecular weight material from human lung cancers [PDF]

, 1981
We have studied the effect of dialysates from lung cancer homogenates to alter both the expression of complement (C3b) receptors per se and also to inhibit leucoattractant-induced enhancement of complement rosettes on monocytes from healthy individuals ...
Kay, A B, Abell, C A, Glass, E J
core  

Combined inhibition of complement (C5) and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis

, 2013
Complement and the TLR family constitute two important branches of innate immunity. We previously showed attenuating effects on inflammation and thromogenicity by inhibiting the TLR coreceptor CD14 in porcine sepsis. In the present study, we explored the
Nunn, Miles, Hellerud, Bernt C., Bongoni, Anjan K., Scott, Helge, Egge, Kjetil, Barratt-Due, Andreas, Pischke, Søren, Sokolov, Andrey, Rieben, Robert, Pharo, Anne, Lindstad, Julie K., Pischke, Soren, Mollnes, Tom E., Thorgersen, Ebbe B.   +13 more
core   +1 more source

Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

Терапевтический архив
Aim. To evaluate the hematological response within 4 weeks of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to long-term eculizumab therapy. Materials and methods.
Olesya U. Klimova, Irina K. Golubovskaya, Yuriy N. Kuznetsov, Maria V. Marchenko, Alexander D. Kulagin   +4 more
doaj   +1 more source

Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy

Oncohematology
The introduction of the complement component C5 inhibitor eculizumab has radically changed the prognosis and quality of life of patients with paroxysmal nocturnal hemoglobinuria. Up to 30 % of patients develop only a suboptimal response to C5 inhibition.
M. V. Marchenko, O. U. Klimova, E. V. Anikina, A. V. Lapina, T. A. Rudakova, T. I. Ksenzova, A. D. Kulagin   +6 more
openaire   +2 more sources

Inhibition of the complement component C5 and the Toll-like receptor molecule CD14 prevents systemic and local kidney inflammation in mice experiencing brain death

Scientific Reports
Brain death (BD) induces a systemic inflammation impairing donor organ quality. Complement and Toll-like receptors (TLRs), with the key co-receptor CD14 molecule, are key innate recognition immune systems.
Tom E. Mollnes, Neeltina M. Jager, Petra J. Ottens, Camilla Schjalm, Zwanida J. Veldhuis, Henri G. D. Leuvenink, Søren E. Pischke   +6 more
doaj   +1 more source